Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis

Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis

Abstract Background Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide, with increased prevalence in individuals with chronic liver conditions and type 2 diabetes mellitus (T2DM). Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) have shown promise in diabetes...

Full description

Saved in:

Bibliographic Details
Main Authors:	Muhammed Shabil, Mahalaqua Nazli Khatib, Suhas Ballal, Pooja Bansal, Balvir S. Tomar, Ayash Ashraf, M. Ravi Kumar, Aashna Sinha, Pramod Rawat, Abhay M. Gaidhane, Sanjit Sah, Afukonyo Shidoiku Daniel, Ambanna Yappalparvi, Ganesh Bushi
Format:	Article
Language:	English
Published:	BMC 2024-11-01
Series:	BMC Endocrine Disorders
Subjects:	Hepatocellular carcinoma Glucagon-like Peptide-1 receptor agonists Type 2 diabetes mellitus Meta-analysis
Online Access:	https://doi.org/10.1186/s12902-024-01775-2
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Association of celiac disease and myocardial infarction: a systematic review and meta-analysis
by: Nikhil Sharma, et al.
Published: (2024-11-01)

Prevalence of suicidal ideation, attempts and associated risk factors in oral cancer patients: a systematic review and meta-analysis
by: Ganesh Bushi, et al.
Published: (2025-01-01)

Prevalence of dual use of combustible tobacco and E-cigarettes among pregnant smokers: a systematic review and meta-analysis
by: Ganesh Bushi, et al.
Published: (2024-11-01)

Lyme disease associated neurological and musculoskeletal symptoms: A systematic review and meta-analysis
by: Ganesh Bushi, et al.
Published: (2025-02-01)

Association of exposure to air pollutants and risk of mortality among people living with HIV: a systematic review
by: Bijaya Kumar Padhi, et al.
Published: (2024-11-01)

Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
by: Muhammed Shabil, et al.
Published: (2024-12-01)

Different post-pancreatectomy glucagon responses to a meal test between surgical approaches
by: Tsuguka Matsuda, et al.
Published: (2023-11-01)

Autophagy-lysosome pathway in insulin & glucagon homeostasis
by: Yi Wu, et al.
Published: (2025-02-01)

Postural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review
by: Ganesh Bushi, et al.
Published: (2024-11-01)

Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes
by: Yuqin Wu, et al.
Published: (2024-12-01)

Characterization of LY3324954 a long-acting glucagon-receptor agonist
by: William Roell, et al.
Published: (2025-01-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

West Nile Virus in a changing climate: epidemiology, pathology, advances in diagnosis and treatment, vaccine designing and control strategies, emerging public health challenges – a comprehensive review
by: Parminder Singh, et al.
Published: (2025-12-01)

Hong Kong's first human case of B virus: Feeding monkeys, a risky practice!
by: Amogh Verma, et al.
Published: (2024-12-01)

Glucagon: a potential protective factor against peripheral nerve compromise in patients with type 2 diabetes and obesity
by: Hao Hua, et al.
Published: (2025-01-01)

Elevated glucagon and postprandial hyperglycemia in fatty liver indicate early glucose intolerance in metabolic dysfunction associated steatotic liver disease
by: Rieko Oikawa, et al.
Published: (2024-12-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Tuberculosis in South Asia: A regional analysis of burden, progress, and future projections using the global burden of disease (1990–2021)
by: Vijay Kumar, et al.
Published: (2024-12-01)

Glucagon, rather than Glucagon-Like Peptide 1, Mediates Higher Post-Lunch Glucose Excursions during Breakfast Skipping in Asian Indian Patients with Uncontrolled Type 2 Diabetes Mellitus
by: Yash V. Chauhan, et al.
Published: (2024-12-01)

Reversible Cerebral Vasoconstriction Syndrome Following Blood Transfusion in a Patient With Chronic Anemia: A Case Report
by: Amogh Verma, et al.
Published: (2024-12-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

A clinical case of asymptomatic pancreatic hyperenzymemia on the background of taking a Glucagon-like peptide-1 analogue (GLP-1)
by: N.A. Sanina, et al.
Published: (2023-09-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review
by: Alicja Skrobucha, et al.
Published: (2024-12-01)

β-glucan attenuates intestinal ischemia-reperfusion injury in mice by promoting glucagon-like peptide-1 secretion
by: WANG Wei, et al.
Published: (2025-01-01)

Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
by: Chien-Tai Hong, et al.
Published: (2024-11-01)

Long-Acting Glucagon-Like Peptide-1 Receptor Agonist-Induced Rheumatoid Arthritis in a Patient with Type 2 Diabetes Mellitus
by: Koji Kikkawa, et al.
Published: (2021-09-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
by: Haijun Wan, et al.
Published: (2024-11-01)

SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
by: Sven O. Göpel, et al.
Published: (2024-11-01)

Addressing the Nipah virus threat: A call for global vigilance and coordinated action
by: Priyanka Mohapatra, et al.
Published: (2024-11-01)

Association between polymorphisms of glucagon-like peptide-1 receptor gene and susceptibility to osteoporosis in Chinese postmenopausal women
by: Xiaoxue Bao, et al.
Published: (2024-12-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 receptor agonists and the risk of erectile dysfunction: a drug target Mendelian randomization study
by: Hongjin An, et al.
Published: (2024-11-01)

Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
by: Luis Alberto Vigara, et al.
Published: (2024-11-01)

Cannabis consumption and risk of asthma: a systematic review and meta-analysis
by: Ajay Malvi, et al.
Published: (2025-01-01)

The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era
by: Parminder Singh, et al.
Published: (2024-12-01)

Effect of glucagon-like peptide-1 receptor agonists on vascular risk factors among adults with type 2 diabetes and established atherosclerotic cardiovascular disease
by: Aaron King, et al.
Published: (2025-03-01)

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
by: Hayeon Kim, et al.
Published: (2024-10-01)